Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study

References

• SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
   PubMed Web of Science ®Google Scholar
• TravisWDBrambillaERielyGJNew pathologic classification of lung cancer: relevance for clinical practice and clinical trialsJ Clin Oncol2013318992100123401443
   PubMed Web of Science ®Google Scholar
• De GeerAErikssonJFinnernHWA cross-country review of data collected on non-small cell lung cancer (NSCLC) patients in cancer registries, databases, retrospective and non-randomized prospective studiesJ Med Econ201316113414922702446
   PubMedGoogle Scholar
• ShigematsuHLinLTakahashiTClinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancersJ Natl Cancer Inst200597533934615741570
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• ZhouCWuY-LChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• SequistLVYangJC-HYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273327333423816960
   PubMed Web of Science ®Google Scholar
• TanFShenXWangDIcotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studiesLung Cancer201276217718222112293
   PubMed Web of Science ®Google Scholar
• ShiYSunYYuJChina experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version)Asia Pac J Clin Oncol20171318710328134505
   PubMed Web of Science ®Google Scholar
• HuXHanBGuAA single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)Lung Cancer201486220721225261231
   PubMed Web of Science ®Google Scholar
• ZhengHWangQShiHZhangHHuFLiBFavorable response to icotinib in a lung cancer patient with a special mutation at exon 19 of epidermal growth factor receptorThorac Cancer20145435836126767025
   PubMedGoogle Scholar
• KobayashiSBoggonTJDayaramTEGFR mutation and resistance of non–small-cell lung cancer to gefitinibN Engl J Med2005352878679215728811
   PubMed Web of Science ®Google Scholar
• OxnardGRMorrisMJHodiFSWhen progressive disease does not mean treatment failure: reconsidering the criteria for progressionJ Natl Cancer Inst2012104201534154122927506
   PubMedGoogle Scholar
• OhI-JBanH-JKimK-SKimY-CRetreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II studyLung Cancer201277112112722333554
   PubMed Web of Science ®Google Scholar
• SongZYuXHeCZhangBZhangYRe-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancerJ Thorac Dis20135440040523991294
   PubMed Web of Science ®Google Scholar
• ChenZFillmoreCMHammermanPSKimCFWongK-KNon-small-cell lung cancers: a heterogeneous set of diseasesNat Rev Cancer201414853554625056707
   PubMed Web of Science ®Google Scholar
• FontaniniGVignatiSBoldriniLVascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinomaClin Cancer Res1997368618659815760
   PubMed Web of Science ®Google Scholar
• TaberneroJThe role of VEGF and EGFR inhibition: implications for combining anti–VEGF and anti–EGFR agentsMol Cancer Res20075320322017374728
   PubMed Web of Science ®Google Scholar
• CiardielloFCaputoRDamianoVAntitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinaseClin Cancer Res2003941546155612684431
   PubMed Web of Science ®Google Scholar
• EllisLMEpidermal growth factor receptor in tumor angiogenesisHematol Oncol Clin North Am20041851007102115474332
   PubMed Web of Science ®Google Scholar
• DanceyJEChenHXStrategies for optimizing combinations of molecularly targeted anticancer agentsNat Rev Drug Discov20065864965916883303
   PubMedGoogle Scholar
• SandlerAHerbstRCombining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathwaysClin Cancer Res20061214 pt 24421s4425s16857821
   PubMedGoogle Scholar
• NaumovGNNilssonMBCasconeTCombined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistanceClin Cancer Res200915103484349419447865
   PubMed Web of Science ®Google Scholar
• IchiharaEHottaKNogamiNPhase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non–small cell lung cancer with activating EGFR gene mutations: The Okayama Lung Cancer Study Group Trial 1001J Thorac Oncol201510348649125695221
   PubMed Web of Science ®Google Scholar
• HerbstRSO’NeillVJFehrenbacherLPhase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancerJ Clin Oncol200725304743475017909199
   PubMed Web of Science ®Google Scholar
• LiJQinSXuJRandomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctionJ Clin Oncol201634131448145426884585
   PubMed Web of Science ®Google Scholar
• ZhangLShiMHuangCA Phase II, Multicenter, Placebo-Controlled Trial of Apatinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) after Two Previous Treatment RegimensAlexandria, VAAmerican Society of Clinical Oncology2012
   Google Scholar
• National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology (NCCN Guidelines™) [homepage on the Internet]Non-Small Cell Lung Cancer (version 4.2017)2017 Available from: http://www.nccn.orgAccessed September 4, 2017
   Google Scholar
• KairaKNaitoTTakahashiTPooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancerLung Cancer20106819910419540616
   PubMedGoogle Scholar
• AsahinaHOizumiSInoueAPhase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinibOncology2011795–6423429
   Google Scholar
• HataAKatakamiNYoshiokaHErlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selectionLung Cancer201174226827321529987
   PubMed Web of Science ®Google Scholar
• KoizumiTAgatsumaTIkegamiKProspective study of gefitinib readministration after chemotherapy in patients with advanced non–small-cell lung cancer who previously responded to gefitinibClin Lung Cancer201213645846322402083
   PubMedGoogle Scholar
• MillerVAHirshVCadranelJAfatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialLancet Oncol201213552853822452896
   PubMed Web of Science ®Google Scholar
• KatakamiNAtagiSGotoKLUX-Lung 4: a phase II trial of afatinib in patients with advanced non–small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or bothJ Clin Oncol201331273335334123816963
   PubMed Web of Science ®Google Scholar
• JanjigianYYAzzoliCGKrugLMPhase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinibClin Cancer Res20111782521252721248303
   PubMed Web of Science ®Google Scholar
• JanjigianYYSmitEFGroenHJDual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor–resistant EGFR-mutant lung cancer with and without T790M mutationsCancer Discov2014491036104525074459
   PubMed Web of Science ®Google Scholar
• CustodioAMéndezMProvencioMTargeted therapies for advanced non-small-cell lung cancer: current status and future implicationsCancer Treat Rev2012381365321592673
   PubMedGoogle Scholar
• RubinBPDuensingAMechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumorsLab Invest2006861098198616924245
   PubMedGoogle Scholar
• TonraJRDeeviDSCorcoranESynergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapyClin Cancer Res20061272197220716609035
   PubMedGoogle Scholar
• OtsukaKHataATakeshitaJEGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancerCancer Chemother Pharmacol201576483584126349474
   PubMed Web of Science ®Google Scholar
• ImaiKTakaokaAComparing antibody and small-molecule therapies for cancerNat Rev Cancer20066971472716929325
   PubMed Web of Science ®Google Scholar
• PengSZhangYPengHIntracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by ApatinibCancer Lett2016373219320226805764
   PubMed Web of Science ®Google Scholar
• PengHZhangQLiJApatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinomaOncotarget2016713172201722926967384
   PubMedGoogle Scholar